Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JESSICA BAUMAN

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1619139235
CMS profile
579955
Location
PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$6,402.50

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $6,402.50 6

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Scientific Affairs, LLC $4,040.00 4
Merck Sharp & Dohme Corporation $1,500.00 1
Eli Lilly and Company $862.50 1

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JESSICA BAUMAN

NPI 1619139235 · CMS profile ID 579955

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1619139235?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JESSICA BAUMAN, NPI 1619139235, CMS profile ID 579955. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619139235?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JESSICA BAUMAN, NPI 1619139235, CMS profile ID 579955. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619139235?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JESSICA BAUMAN, NPI 1619139235, CMS profile ID 579955, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1619139235?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $6,402.50 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eli Lilly and Company $862.5005/19/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819152671 CMS
Merck Sharp & Dohme Corporation $1,500.0005/05/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848308513 CMS
Janssen Scientific Affairs, LLC $1,010.0003/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788484599 CMS
Janssen Scientific Affairs, LLC $1,010.0003/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788484601 CMS
Janssen Scientific Affairs, LLC $1,010.0003/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788484603 CMS
Janssen Scientific Affairs, LLC $1,010.0003/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788484605 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,346.90 6
PY2021 $6,402.50 6
PY2022 $2,520.00 1
PY2023 $13,235.53 5
PY2024 $3,945.00 3
PY2025 $4,182.50 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $662,530.20 43
PY2024 Recipient $4,600.00 2
PY2024 Principal investigator $597,434.60 56
PY2023 Recipient $3,200.00 1
PY2023 Principal investigator $615,260.38 77
PY2022 Principal investigator $513,473.56 47
PY2021 Principal investigator $536,056.62 88
PY2020 Recipient $3,200.00 1
PY2020 Principal investigator $550,482.65 74
PY2019 Principal investigator $501,598.41 22

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

75 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $350.00 12/17/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 740743077
Principal investigator 1 Merck Sharp & Dohme Corporation $9,000.00 12/17/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740743081
Principal investigator 1 Merck Sharp & Dohme Corporation $618.52 12/02/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740743127
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 11/18/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 734928979
Principal investigator 1 Merck Sharp & Dohme Corporation $195.20 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740702593
Principal investigator 1 Merck Sharp & Dohme Corporation $271.17 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740702595
Principal investigator 1 Merck Sharp & Dohme Corporation $15.64 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740702597
Principal investigator 1 Merck Sharp & Dohme Corporation $32.55 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740702599
Principal investigator 1 Merck Sharp & Dohme Corporation $47.25 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740702601
Principal investigator 1 Merck Sharp & Dohme Corporation $65.89 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740702603
Principal investigator 1 Merck Sharp & Dohme Corporation $78.75 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740702605
Principal investigator 1 Merck Sharp & Dohme Corporation $15.75 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740703085
Principal investigator 1 Merck Sharp & Dohme Corporation $20.75 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740703087
Principal investigator 1 Merck Sharp & Dohme Corporation $22.44 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740703089
Principal investigator 1 Merck Sharp & Dohme Corporation $253.23 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740703125
Principal investigator 1 Merck Sharp & Dohme Corporation $62.25 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740703127
Principal investigator 1 Merck Sharp & Dohme Corporation $63.00 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740703129
Principal investigator 1 Merck Sharp & Dohme Corporation $30.92 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740703131
Principal investigator 1 Merck Sharp & Dohme Corporation $35.16 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740703133
Principal investigator 1 Merck Sharp & Dohme Corporation $6.50 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740703169
Principal investigator 1 Merck Sharp & Dohme Corporation $62.25 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740703171
Principal investigator 1 Merck Sharp & Dohme Corporation $76.00 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740703173
Principal investigator 1 Merck Sharp & Dohme Corporation $78.75 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740703175
Principal investigator 1 Merck Sharp & Dohme Corporation $1.95 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740703177
Principal investigator 1 Merck Sharp & Dohme Corporation $136.00 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740703217
Principal investigator 1 Merck Sharp & Dohme Corporation $8.55 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740703223
Principal investigator 1 Merck Sharp & Dohme Corporation $8.85 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740703225
Principal investigator 1 Innate Pharma, Inc $26,009.80 11/06/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 714615829
Principal investigator 1 PFIZER INC. $20,241.00 10/15/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS No dispute reported 06/30/2026 742906241
Principal investigator 1 PFIZER INC. $27,918.00 10/15/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS No dispute reported 06/30/2026 742908155
Principal investigator 1 PFIZER INC. $21,222.00 10/15/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS No dispute reported 06/30/2026 742908937
Principal investigator 1 PFIZER INC. $19,941.00 10/15/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS No dispute reported 06/30/2026 742910133
Principal investigator 1 PFIZER INC. $16,294.00 10/15/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS No dispute reported 06/30/2026 742910529
Principal investigator 1 PFIZER INC. $34,553.00 10/15/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS No dispute reported 06/30/2026 742910895
Principal investigator 1 PFIZER INC. $4,000.00 10/15/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS No dispute reported 06/30/2026 742911923
Principal investigator 1 PFIZER INC. $9,098.00 10/15/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS No dispute reported 06/30/2026 742912071
Principal investigator 1 Merck Sharp & Dohme Corporation $1,541.00 10/13/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 740742743
Principal investigator 1 Genentech, Inc. $3,180.00 10/01/2020 Non-covered Recipient Entity
THE INSTITUTE FOR CANCER RESEARCH
ATEZOLIZUMAB VERSUS PLACEBO AS ADJUVANT THERAPY IN LOCALLY ADVANCED HEAD AND NECK CANCER No dispute reported 06/30/2026 743166311
Principal investigator 1 PFIZER INC. $3,838.00 08/26/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK No dispute reported 06/30/2026 742907337
Principal investigator 1 PFIZER INC. $3,838.00 08/26/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK No dispute reported 06/30/2026 742909979
Principal investigator 1 GlaxoSmithKline, LLC. $12,500.00 08/10/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 734905281
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 08/10/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 734908715
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 08/10/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 734908885
Principal investigator 1 GlaxoSmithKline, LLC. $3,000.00 08/10/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 734909695
Principal investigator 1 GlaxoSmithKline, LLC. $670.00 08/10/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 734910501
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 08/10/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 734921445
Principal investigator 1 GlaxoSmithKline, LLC. $250.00 08/10/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 734921447
Recipient PFIZER INC. $3,200.00 08/07/2020 Covered Recipient Physician LORLATINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 742856131
Principal investigator 1 PFIZER INC. $3,838.00 07/29/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK No dispute reported 06/30/2026 742907481
Principal investigator 1 Merck Sharp & Dohme Corporation $2,000.00 07/23/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 740743259
Principal investigator 1 Merck Sharp & Dohme Corporation $2,000.00 07/22/2020 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A Phase III Randomized Trial of MK-3475 Versus Standard Treatment in Subjects with recurrent or metastatic head and neck cancer No dispute reported 06/30/2026 740779939
Principal investigator 1 Merck Sharp & Dohme Corporation $8,232.00 07/03/2020 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A Phase III Randomized Trial of MK-3475 Versus Standard Treatment in Subjects with recurrent or metastatic head and neck cancer No dispute reported 06/30/2026 740779891
Principal investigator 1 Merck Sharp & Dohme Corporation $10,788.80 07/03/2020 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A Phase III Randomized Trial of MK-3475 Versus Standard Treatment in Subjects with recurrent or metastatic head and neck cancer No dispute reported 06/30/2026 740779895
Principal investigator 1 Merck Sharp & Dohme Corporation $11,943.63 07/03/2020 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A Phase III Randomized Trial of MK-3475 Versus Standard Treatment in Subjects with recurrent or metastatic head and neck cancer No dispute reported 06/30/2026 740779937
Principal investigator 1 Merck Sharp & Dohme Corporation $350.00 06/18/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 740743301
Principal investigator 1 PFIZER INC. $9,551.10 06/17/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK No dispute reported 06/30/2026 742908261
Principal investigator 1 PFIZER INC. $11,845.33 06/11/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS No dispute reported 06/30/2026 742908403
Principal investigator 1 Innate Pharma, Inc $57,350.44 06/01/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 714615835
Principal investigator 1 Innate Pharma, Inc $2,600.00 06/01/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 714615837
Principal investigator 1 PFIZER INC. $3,838.00 05/27/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK No dispute reported 06/30/2026 742906633
Principal investigator 1 PFIZER INC. $3,500.00 05/27/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK No dispute reported 06/30/2026 742910485
Principal investigator 1 Merck Sharp & Dohme Corporation $2,500.00 05/13/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase III Randomized Trial of MK-3475 Versus Standard Treatment in Subjects with recurrent or metastatic head and neck cancer No dispute reported 06/30/2026 740743211
Principal investigator 1 Merck Sharp & Dohme Corporation $350.00 05/12/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 740743299
Principal investigator 1 Innate Pharma, Inc $3,900.00 04/17/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 714615833
Principal investigator 1 PFIZER INC. $3,838.00 04/07/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK No dispute reported 06/30/2026 742905839
Principal investigator 1 PFIZER INC. $7,676.00 04/07/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK No dispute reported 06/30/2026 742908537
Principal investigator 1 Merck Sharp & Dohme Corporation $3,082.00 03/24/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 740743249
Principal investigator 1 PFIZER INC. $13,437.00 03/11/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK No dispute reported 06/30/2026 742910099
Principal investigator 1 PFIZER INC. $10,953.00 03/11/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK No dispute reported 06/30/2026 742910905
Principal investigator 1 PFIZER INC. $3,838.00 03/11/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK No dispute reported 06/30/2026 742912527
Principal investigator 1 Merck Sharp & Dohme Corporation $10,070.00 02/27/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 740743247
Principal investigator 1 Innate Pharma, Inc $10,937.70 02/14/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 714615831
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $12,454.36 02/06/2020 Non-covered Recipient Entity
Fox Chase Cancer Center-parent Account
Phase I II FIH ICOS Monotherapy Ipi Combination No dispute reported 06/30/2026 736759865
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,545.22 01/09/2020 Non-covered Recipient Entity
Institute For Cancer Research
Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation, T790M No dispute reported 06/30/2026 736760287
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $104,912.95 01/06/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
Phase I II FIH ICOS Monotherapy Ipi Combination No dispute reported 06/30/2026 736758581